Kathleen B. M. Claes - Genetic Mutations

Author Information

Kathleen B. M. Claes is a distinguished researcher affiliated with the Center for Medical Genetics at Ghent University Hospital in Ghent, Belgium. Her work primarily focuses on genetics and its application in diagnosing and understanding various cancers.

Research Contributions

Dr. Claes has made significant contributions to the field of medical genetics, particularly in the context of cancer research. Her studies have covered a wide range of topics, including the application of ultrasensitive NGS-based blood tests for early-stage lung cancer diagnosis, the identification of genetic modifiers of breast cancer risk, and the prevalence of germline pathogenic variants in cancer-predisposing genes. Notably, she has also contributed to understanding the polygenic risk modeling for epithelial ovarian cancer and the challenges associated with microsatellite instability detection in colorectal and endometrial cancer. Her work is highly regarded, as evidenced by her numerous publications and their high citation count.

Aliases

Dr. Claes is known by several aliases in the academic community, including Kathleen B. M. Claes, Kathleen Bm. Claes, K. B. M. Claes, and Kathleen B.m. Claes, among others. These variations in her name are often seen across different publications and citations.

Publication and Citation Metrics

Metric	Value
Citation Count	8133
h-index	52
Paper Count	213

Publications:

Application of an Ultrasensitive NGS-Based Blood Test for the Diagnosis of Early-Stage Lung Cancer: Sensitivity, a Hurdle Still Difficult to Overcome

DOI: 10.3390/cancers14082031

Year: 2022

TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

DOI: 10.1084/jem.20211381

Year: 2022

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

DOI: 10.1038/s41431-022-01085-y

Year: 2022

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

DOI: 10.1038/s41431-021-00987-7

Year: 2022

Comparison of Microsatellite Instability Detection by Immunohistochemistry and Molecular Techniques in Colorectal and Endometrial Cancer

DOI: 10.21203/RS.3.RS-130862/V1

Year: 2021

Somatic mosaics in hereditary tumor predisposition syndromes.

DOI: 10.1016/j.ejmg.2021.104360

Year: 2021

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

DOI: 10.1038/s41467-020-20496-3

Year: 2021

Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients

DOI: 10.3390/cancers13174430

Year: 2021

Dealing with Pseudogenes in Molecular Diagnostics in the Next Generation Sequencing Era.

DOI: 10.1007/978-1-0716-1503-4_22

Year: 2021

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

DOI: 10.1093/jnci/djab147

Year: 2021

What is PacBio?

What Are Some Key Considerations for Successful Sanger Sequencing?

How do Genetic Mutations Affect Health?

How do Chemical Mutagens Cause Induced Mutations?

How Does it Differ from Autosomal Dominant Inheritance?

What are Mutagens?

Which Genes Are Commonly Involved?

How is Gene Amplification Detected?

How are Patients Monitored During TKI Therapy?

What is a Mutation?

Partnered Content Networks

Relevant Topics